I think the pricing is an implicit way the cog in the engine works. I don't necessarily agree with it, but I see it and always think about it when anybody poin

I think the pricing is an implicit way the cog in the engine works. I don't necessarily agree with it, but I see it and always think about it when anybody points out how expensive medical care is here in the USA. Biotech R&D advances in the USA are funded by monstrously price gouging insurance companies. Are you a biotech innovator? Your best bet is to start in the USA because you can charge a lot of money and nobody will lift a finger that influences your market potential like what happens in other countries. Hopefully a large pharma company will buy your small pharma or medical device company because they have 2 things you don't: 1. Distribution - 1 sales rep for every doctor 2. Synthetic Scaling Insight - They have deep insights and grandfathered advantages in this arena, lest you can double down on putting in 40M-100M to make it happen. ---Or so this was the way it was explained to me through hundreds of interactions trying to build a genetics company in the USA. --- The hunt for drug targets is the elusive hunt for the black swan. There's 8-10 new genetic tests that come out each day but very few if any of them can be tied to something specific, because it's tough. Data doesn't necessarily make it easier, despite the notion of big-data optimization. As such, prices will get higher, before they get lower. That or drug dev. stagnates. The elephant in the room anytime we talk about US healthcare is our flawed food environment - Sugar. It's creeping up on other countries fast.....